Catamaran Innovation Center, 300 N. LaSalle St., Ste. 1600, Chicago, IL 60654.
J Manag Care Spec Pharm. 2014 Jul;20(7):703-13. doi: 10.18553/jmcp.2014.20.7.703.
Evidence of the associations between statin adherence level, health care costs, and utilization is still limited. It is not clear whether better clinical outcomes derived from increasing statin adherence levels can be translated into cost savings and lower health care utilization.
To evaluate the associations between statin adherence level, health care costs, hospital admission, and emergency room (ER) visits after statin therapy is taken for 1 year.
A retrospective cohort study was performed to examine whether higher statin adherence level, measured as medication possession ratio (MPR), is associated with lower health care costs and hospital admission rate and with fewer ER visits. The study sample consisted of adult patients aged 18-64 years on an index date with continuous enrollment 12 months prior to and 12 months after the index date (the first fill date of a statin between January 1, 2009, and December 31, 2010). Study subjects also needed to have a minimum of 2 ICD-9-CM diagnoses for hyperlipidemia or diabetes in the pre-index date period. Main data sources were medical and prescription (Rx) claims, as well as enrollment files provided by a health benefit program and a medical carrier of state government and public school employees in a midwestern state. Study subjects were stratified into 8 groups based on statin MPR level: less than 40%, 40%-59%, 60%-69%, 70%-79%, 80%-84%, 85%-89%, 90%-95%, and 96%-100%. Total medical and Rx costs, as well as all-cause hospital admission rates and ER visits in a year after the index date, were computed based on medical and Rx claims. A separate breakout of statin costs, part of total Rx costs, was also computed. Generalized linear models (GLMs) were developed to test the hypothesis that higher statin adherence levels are associated with lower health care costs and utilization.
A total of 10,312 subjects met the criteria and were selected. The average statin MPR in a year after the index date was 71.95%. Mean total costs (medical + Rx) in a year after the index date were $6,064.36. There were significant variations in Rx costs and total health care costs as well as ER visits among the 8 patient groups stratified using the statin MPR level. A GLM model showed that all the ratios of health care costs among groups with statin MPR from 40%-59%, 60%-69%, 80%-84%, 85%-89%, 90%-95%, and 96%-100% were larger than 1 and statistically significant compared with the reference group with statin MPR less than 40%, suggesting those groups had higher health care costs than the reference group with the lowest statin MPR level. Based on a logistic regression model of hospital utilization for this study population, all the odds ratios of all-cause hospitalization among the groups with higher statin MPR were not statistically significant, suggesting that the likelihood of hospitalization for patients with higher statin MPR was not statistically lower than that of the reference group with statin MPR less than 40%. After controlling for all other covariates, another GLM model based on the Poisson distribution and log link function showed that ratios of ER visits among groups with statin MPR from 60%-69%, 80%-84%, 85%-89%, 90%-95%, and 96%-100% were smaller than 1 and statistically significant, suggesting the groups had fewer ER visits than the reference group with statin MPR less than 40%. The patient group with statin MPR from 96%-100% was estimated to have the lowest number of ER visits.
Our study results show that much higher statin adherence levels are related to fewer ER visits after statin treatment is taken for a year among beneficiaries; however, the study is inconclusive whether higher statin adherence levels are associated with lower overall health care costs in a year after statin therapy is taken. Further research is needed to evaluate the associations between statin adherence level, the cost of cardiovascular care alone, and utilization over a longer period.
他汀类药物依从性水平、医疗保健成本和利用之间的关联证据仍然有限。目前尚不清楚从提高他汀类药物依从性水平中获得的更好的临床结果是否可以转化为成本节约和降低医疗保健利用率。
评估他汀类药物治疗 1 年后,他汀类药物依从性水平与医疗保健成本、住院率和急诊室(ER)就诊之间的关系。
进行了一项回顾性队列研究,以检验更高的他汀类药物依从性水平(以药物占有比[MPR]衡量)是否与较低的医疗保健成本和住院率以及较少的 ER 就诊有关。研究样本包括年龄在 18-64 岁的成年患者,他们在索引日期前连续 12 个月和索引日期后 12 个月(2009 年 1 月 1 日至 2010 年 12 月 31 日期间首次服用他汀类药物的第一剂)有连续的参保记录。研究对象还需要在索引日期前的时期内有至少 2 次 ICD-9-CM 诊断为高脂血症或糖尿病。主要数据来源包括医疗和处方(Rx)索赔,以及由健康福利计划和州政府和公立学校员工医疗保险公司提供的参保文件。研究对象根据他汀类药物 MPR 水平分为 8 组:小于 40%、40%-59%、60%-69%、70%-79%、80%-84%、85%-89%、90%-95%和 96%-100%。根据医疗和 Rx 索赔计算了索引日期后一年的总医疗和 Rx 费用以及全因住院率和 ER 就诊次数。还计算了他汀类药物费用的单独细分,这是 Rx 总费用的一部分。开发了广义线性模型(GLM)来检验以下假设:他汀类药物依从性水平较高与较低的医疗保健成本和利用率有关。
共有 10312 名符合条件的患者入选。索引日期后一年的平均他汀类药物 MPR 为 71.95%。索引日期后一年的总费用(医疗+Rx)平均为 6064.36 美元。在使用他汀类药物 MPR 分层的 8 个患者组中,Rx 费用和总医疗保健费用以及 ER 就诊次数存在显著差异。GLM 模型显示,来自 40%-59%、60%-69%、80%-84%、85%-89%、90%-95%和 96%-100%的 MPR 比值的医疗保健成本比参考组的比值均大于 1,且统计学上与他汀类药物 MPR 小于 40%的参考组相比具有显著差异,表明这些组的医疗保健成本高于他汀类药物 MPR 最低水平的参考组。基于该研究人群的住院利用情况的逻辑回归模型,所有较高他汀类药物 MPR 组的全因住院的优势比均无统计学意义,表明较高他汀类药物 MPR 患者的住院可能性与他汀类药物 MPR 小于 40%的参考组无统计学差异。在控制所有其他协变量后,基于泊松分布和对数链接函数的另一个 GLM 模型显示,来自 60%-69%、80%-84%、85%-89%、90%-95%和 96%-100%的 MPR 比值均小于 1,且统计学上显著,表明这些组的 ER 就诊次数少于他汀类药物 MPR 小于 40%的参考组。他汀类药物 MPR 为 96%-100%的患者组估计 ER 就诊次数最少。
我们的研究结果表明,他汀类药物治疗 1 年后,较高的他汀类药物依从性水平与接受他汀类药物治疗后 ER 就诊次数较少有关;然而,关于他汀类药物依从性水平与他汀类药物治疗后一年的整体医疗保健成本之间是否存在关联,研究结果尚无定论。需要进一步研究评估他汀类药物依从性水平、心血管保健成本和使用情况之间的关联,以及更长时间内的利用情况。